

mSMART, Plasma Cell Proliferative Disorder, FISH, Bone Marrow

### Overview

#### **Useful For**

Detecting, at diagnosis, recurrent common high-risk chromosome abnormalities associated with multiple myeloma or other plasma cell proliferative disorders, using a laboratory-designated probe set algorithm

Identifying prognostic markers associated with multiple myeloma or other plasma cell proliferative disorders

#### **Reflex Tests**

Test Id	Reporting Name	Available Separately	Always Performed
MPCDB	Probe, Each Additional	No, (Bill Only)	No
	(MPCDS)		

## **Testing Algorithm**

This test includes a charge for the probe application, analysis, and professional interpretation of results for 1 probe set (2 individual fluorescence in situ hybridization [FISH] probes) on pre-sorted plasma cells. Additional charges will be incurred for all reflex or additional probe sets performed. Analysis charges will be incurred based on the number of cells analyzed per probe set. If an insufficient number of plasma cells are available for analysis, no analysis charges will be incurred.

If sufficient plasma cells are identified, the plasma cell FISH panel includes testing for the following abnormalities using the FISH probes listed:

1p loss/1q gain, CDKN2C/1q22 probe set

t(8q24.21;var) or MYC rearrangement, MYC break-apart probe set

t(14q32;var) or IGH rearrangement, IGH break-apart probe set

-17/17p-, TP53/D17Z1 probe set

If an *IGH* rearrangement is identified, appropriate reflex testing will be performed in an attempt to identify the translocation partner using the FISH probes listed:

t(4;14)(p16.3;q32) IGH::FGFR3 fusion, FGFR3/IGH probe set

t(6;14)(p21;q32) IGH::CCND3 fusion, CCND3/IGH probe set

t(11;14)(q13;q32) or IGH::CCND1 fusion, CCND1/IGH probe set

t(14;16)(q32;q23) IGH::MAF fusion, IGH/MAF probe set

t(14;20)(q32;q12) IGH::MAFB fusion, IGH/MAFB probe set

Hyperdiploidy, as determined by flow cytometry, will be incorporated into the final interpretation. For samples with an unsuccessful flow evaluation for hyperdiploidy and sufficient plasma cells, FISH testing for the following abnormalities will be performed using the probes listed:

- +3 (trisomy 3) and/or +7 (trisomy 7), D3Z1/D7Z1 probe set
- +9 (trisomy 9) and/or +15 (trisomy 15), D9Z1/D15Z4 probe set



mSMART, Plasma Cell Proliferative Disorder, FISH, Bone Marrow

Appropriate ancillary probes may be performed at consultant discretion to render comprehensive assessment. Any additional probes will have the results included within the final report and will be performed at an additional charge.

## **Method Name**

Only orderable as part of a profile. For more information see MSMRT / Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report, Bone Marrow.

Fluorescence In Situ Hybridization (FISH)

### **NY State Available**

Yes

# Specimen

# **Specimen Type**

**Bone Marrow** 

# **Specimen Required**

Only orderable as part of a profile. For more information see MSMRT / Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report, Bone Marrow.

Specimen Type: Redirected bone marrow

Preferred: Yellow top (ACD)

Acceptable: Lavender top (EDTA) or green top (heparin)

Specimen Volume: 4 mL

# Specimen Minimum Volume

2 mL

# **Reject Due To**

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

# **Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Bone Marrow	Ambient (preferred)		
	Refrigerated		

# **Clinical & Interpretive**

# **Clinical Information**



mSMART, Plasma Cell Proliferative Disorder, FISH, Bone Marrow

Multiple myeloma is a hematologic neoplasm that generally originates in the bone marrow and develops from malignant plasma cells. There are 4 main categories of plasma cell proliferative disorders: monoclonal gammopathy of undetermined significance (MGUS), monoclonal immunoglobulin deposition diseases (amyloidosis), plasmacytoma, and multiple myeloma. MGUS, which occurs in 3% to 4% of individuals over age 50 years, represents the identification of an asymptomatic monoclonal protein, yet approximately 1% per year will progress to multiple myeloma. Amyloidosis represents a rare group of deposition disorders including primary amyloidosis vs. light-chain and heavy-chain disease. Plasmacytomas represent isolated collections of bone or extramedullary plasma cells with a risk for development of multiple myeloma. Generalized bone pain, anemia, limb numbness or weakness, symptoms of hypercalcemia, and recurrent infections are all symptoms that may indicate multiple myeloma.

As myeloma progresses, the malignant plasma cells interfere with normal blood product formation in the bone marrow, resulting in anemia and leukopenia. Myeloma also causes an overstimulation of osteoclasts, causing excessive breakdown of bone tissue without the normal corresponding bone formation. These bone lesions are seen in approximately 66% of myeloma patients. In advanced disease, bone loss may reach a degree where the patient suffers fractures easily.

Multiple myeloma is increasingly recognized as a disease characterized by marked cytogenetic, molecular, and proliferative heterogeneity. This heterogeneity is manifested clinically by varying degrees of disease aggressiveness. Patients with more aggressive multiple myeloma experience suboptimal responses to some therapeutic approaches; therefore, identifying these patients is critically important for selecting appropriate treatment options.

## **Reference Values**

Only orderable as part of a profile. For more information see MSMRT / Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report, Bone Marrow.

An interpretive report will be provided.

# Interpretation

A neoplastic clone is detected when the percentage of cells with an abnormality exceeds the normal reference range for any given probe set.

The absence of an abnormal clone does not rule out the presence of neoplastic disorder.

#### **Cautions**

This test is not approved by the US Food and Drug Administration, and it is best used as an adjunct to existing clinical and pathologic information.

If no fluorescence in situ hybridization (FISH) signals are observed post-hybridization, the case will be released indicating a lack of FISH results.

If an insufficient number or plasma cells are identified in the sample, the case will be cancelled.

## Clinical Reference

1. WHO Classification of Tumours Editorial Board, eds. Haematolymphoid tumours. 5th ed. IARC Press; 2024:603-630. WHO Classification of Tumours. Vol 11



mSMART, Plasma Cell Proliferative Disorder, FISH, Bone Marrow

- 2. Arber D., Borowitz, Cook J, et al. The International Consensus Classification of Myeloid and Lymphoid Neoplasms. Wolter Kluwer; 2025:384-396
- 3. Kumar SK, Rajkumar SV. The multiple myelomas-current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol. 2018;15(7):409-421. doi:10.1038/s41571-018-0018-y
- 4. Lu X, Andersen EF, Banerjee R, et al. Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group. Blood Cancer J. 2025;15(1):86
- 5. Gagnon MF, Midthun SM, Fangel JA, et al. Superior detection rate of plasma cell FISH using FACS-FISH. Am J Clin Pathol. 2024;161(1):60-70. doi:10.1093/ajcp/aqad108

#### **Performance**

# **Method Description**

This test is performed using commercially available and laboratory-developed probes on sorted plasma cells. Deletion of the *TP53* locus from chromosome 17 or monosomy 17 and deletion of the *CDKN2C* locus or gain of the 1q22 locus are detected using enumeration strategy probe sets. If necessary, hyperdiploidy will be assessed using enumeration strategy probe sets for chromosomes 3, 7, 9, and 15. Rearrangements involving *IGH* and *MYC* are detected using dual-color break-apart strategy probe sets. Dual-color, dual-fusion fluorescence in situ hybridization strategy probe sets are used when a rearrangement of the *IGH* gene is detected. For each probe set, 50 plasma cells (if possible) are scored and the result for each probe is reported. (Unpublished Mayo method)

## **PDF Report**

No

# Day(s) Performed

Monday through Friday

### Report Available

7 to 10 days

# **Specimen Retention Time**

14 days

# **Performing Laboratory Location**

Mayo Clinic Laboratories - Rochester Main Campus

### Fees & Codes

#### **Fees**

- Authorized users can sign in to <u>Test Prices</u> for detailed fee information.
- Clients without access to Test Prices can contact <u>Customer Service</u> 24 hours a day, seven days a week.



mSMART, Plasma Cell Proliferative Disorder, FISH, Bone Marrow

Prospective clients should contact their account representative. For assistance, contact <u>Customer Service</u>.

# **Test Classification**

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

#### **CPT Code Information**

88271 x 2, 88274, 88291-FISH Probe, Analysis, Interpretation; 1 probe set 88271 x 2, 88274-FISH Probe, Analysis; each additional probe set (if appropriate)

### **LOINC®** Information

Test ID	Test Order Name	Order LOINC® Value
MPCDS	mSMART Eval, PCPDs, FISH	93357-2

Result ID	Test Result Name	Result LOINC® Value
606091	mSMART Result Summary	62357-9
606092	mSMART Evaluation	57802-1
606093	Interpretation	69965-2
606094	Result Table	93356-4
606095	Result	62356-1
606096	Reason for Referral	42349-1
606097	Specimen	31208-2
606098	Source	85298-8
606099	Method	85069-3
606100	Additional Information	48767-8
606101	Disclaimer	62364-5
606102	Released By	18771-6